BioNTech SE - Asset Resilience Ratio
BioNTech SE (22UA) has an Asset Resilience Ratio of 20.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of BioNTech SE for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how BioNTech SE's Asset Resilience Ratio has changed over time. See shareholders equity of BioNTech SE for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BioNTech SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 22UA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €4.43 Billion | 20.74% |
| Total Liquid Assets | €4.43 Billion | 20.74% |
Asset Resilience Insights
- Good Liquidity Position: BioNTech SE maintains a healthy 20.74% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
BioNTech SE Industry Peers by Asset Resilience Ratio
Compare BioNTech SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for BioNTech SE (2016–2024)
The table below shows the annual Asset Resilience Ratio data for BioNTech SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.17% | €7.02 Billion ≈ $8.21 Billion |
€22.53 Billion ≈ $26.34 Billion |
+9.93pp |
| 2023-12-31 | 21.23% | €4.89 Billion ≈ $5.71 Billion |
€23.01 Billion ≈ $26.90 Billion |
+20.42pp |
| 2022-12-31 | 0.81% | €189.40 Million ≈ $221.43 Million |
€23.28 Billion ≈ $27.22 Billion |
-1.60pp |
| 2021-12-31 | 2.41% | €381.60 Million ≈ $446.13 Million |
€15.83 Billion ≈ $18.51 Billion |
-3.51pp |
| 2020-12-31 | 5.92% | €137.23 Million ≈ $160.44 Million |
€2.32 Billion ≈ $2.71 Billion |
+5.71pp |
| 2019-12-31 | 0.21% | €1.68 Million ≈ $1.96 Million |
€797.65 Million ≈ $932.53 Million |
+0.16pp |
| 2018-12-31 | 0.05% | €336.00K ≈ $392.82K |
€652.99 Million ≈ $763.41 Million |
-0.01pp |
| 2017-12-31 | 0.07% | €246.00K ≈ $287.60K |
€374.71 Million ≈ $438.08 Million |
-0.33pp |
| 2016-12-31 | 0.39% | €1.53 Million ≈ $1.79 Million |
€389.96 Million ≈ $455.90 Million |
-- |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which… Read more